## Rishi J Desai

## List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7323991/publications.pdf

Version: 2024-02-01

126708 118652 4,725 135 33 62 citations h-index g-index papers 137 137 137 6801 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Network-based approach to prediction and population-based validation of in silico drug repurposing. Nature Communications, 2018, 9, 2691.	5.8	351
2	Alternative approaches for confounding adjustment in observational studies using weighting based on the propensity score: a primer for practitioners. BMJ: British Medical Journal, 2019, 367, 15657.	2.4	304
3	Increase in Prescription Opioid Use During Pregnancy Among Medicaid-Enrolled Women. Obstetrics and Gynecology, 2014, 123, 997-1002.	1.2	291
4	Antipsychotic Use in Pregnancy and the Risk for Congenital Malformations. JAMA Psychiatry, 2016, 73, 938.	6.0	206
5	Antidepressant Use Late in Pregnancy and Risk of Persistent Pulmonary Hypertension of the Newborn. JAMA - Journal of the American Medical Association, 2015, 313, 2142.	3.8	198
6	Lithium Use in Pregnancy and the Risk of Cardiac Malformations. New England Journal of Medicine, 2017, 376, 2245-2254.	13.9	183
7	Emulating Randomized Clinical Trials With Nonrandomized Real-World Evidence Studies. Circulation, 2021, 143, 1002-1013.	1.6	174
8	A Propensity-score-based Fine Stratification Approach for Confounding Adjustment When Exposure Is Infrequent. Epidemiology, 2017, 28, 249-257.	1.2	164
9	Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes. JAMA Network Open, 2020, 3, e1918962.	2.8	152
10	Risk of serious infections in tocilizumab versus other biologic drugs in patients with rheumatoid arthritis: a multidatabase cohort study. Annals of the Rheumatic Diseases, 2019, 78, 456-464.	0.5	139
11	Assessment of Cardiovascular Risk in Older Patients With Gout Initiating Febuxostat Versus Allopurinol. Circulation, 2018, 138, 1116-1126.	1.6	108
12	Association of Maternal First-Trimester Ondansetron Use With Cardiac Malformations and Oral Clefts in Offspring. JAMA - Journal of the American Medical Association, 2018, 320, 2429.	3.8	90
13	Comparative Risk of Venous Thromboembolism in Rheumatoid Arthritis Patients Receiving Tofacitinib Versus Those Receiving Tumor Necrosis Factor Inhibitors: An Observational Cohort Study. Arthritis and Rheumatology, 2019, 71, 892-900.	2.9	81
14	Angiotensin-Converting Enzyme Inhibitors and the Risk of Congenital Malformations. Obstetrics and Gynecology, 2017, 129, 174-184.	1.2	77
15	Tofacitinib and risk of cardiovascular outcomes: results from the Safety of TofAcitinib in Routine care patients with Rheumatoid Arthritis (STAR-RA) study. Annals of the Rheumatic Diseases, 2022, 81, 798-804.	0.5	76
16	Topiramate use early in pregnancy and the risk of oral clefts. Neurology, 2018, 90, e342-e351.	1.5	70
17	Cardiovascular Risks of ProbenecidÂVersus Allopurinol in OlderÂPatients WithÂGout. Journal of the American College of Cardiology, 2018, 71, 994-1004.	1.2	69
18	Association of Osteoporosis Medication Use After Hip Fracture With Prevention of Subsequent Nonvertebral Fractures. JAMA Network Open, 2018, 1, e180826.	2.8	64

#	Article	IF	CITATIONS
19	Continuation of Atypical Antipsychotic Medication During Early Pregnancy and the Risk of Gestational Diabetes. American Journal of Psychiatry, 2018, 175, 564-574.	4.0	61
20	Pregabalin use early in pregnancy and the risk of major congenital malformations. Neurology, 2017, 88, 2020-2025.	1.5	56
21	Identification of smoking using Medicare data - a validation study of claims-based algorithms. Pharmacoepidemiology and Drug Safety, 2016, 25, 472-475.	0.9	55
22	Comparative Cardiovascular Risk of Abatacept and Tumor Necrosis Factor Inhibitors in Patients With Rheumatoid Arthritis With and Without Diabetes Mellitus: A Multidatabase Cohort Study. Journal of the American Heart Association, 2018, 7, .	1.6	55
23	Comparative effectiveness of generic and brand-name medication use: A database study of US health insurance claims. PLoS Medicine, 2019, 16, e1002763.	3.9	55
24	Placental Complications Associated With Psychostimulant Use in Pregnancy. Obstetrics and Gynecology, 2017, 130, 1192-1201.	1.2	50
25	Risk of serious infections associated with use of immunosuppressive agents in pregnant women with autoimmune inflammatory conditions: cohort study. BMJ: British Medical Journal, 2017, 356, j895.	2.4	50
26	Association of Preoperative Opioid Use With Mortality and Short-term Safety Outcomes After Total Knee Replacement. JAMA Network Open, 2019, 2, e198061.	2.8	48
27	Cardiovascular (CV) Risk after Initiation of Abatacept versus TNF Inhibitors in Rheumatoid Arthritis Patients with and without Baseline CV Disease. Journal of Rheumatology, 2018, 45, 1240-1248.	1.0	45
28	Risk of admission to hospital for serious infection after initiating tofacitinib versus biologic DMARDs in patients with rheumatoid arthritis: a multidatabase cohort study. Lancet Rheumatology, The, 2020, 2, e84-e98.	2.2	45
29	Association of Ustekinumab vs TNF Inhibitor Therapy With Risk of Atrial Fibrillation and Cardiovascular Events in Patients With Psoriasis or Psoriatic Arthritis. JAMA Dermatology, 2019, 155, 700.	2.0	43
30	Prevalence, incidence and cause-specific mortality of rheumatoid arthritis–associated interstitial lung disease among older rheumatoid arthritis patients. Rheumatology, 2021, 60, 3689-3698.	0.9	43
31	Risk of malignancy associated with use of tocilizumab versus other biologics in patients with rheumatoid arthritis: A multi-database cohort study. Seminars in Arthritis and Rheumatism, 2019, 49, 222-228.	1.6	42
32	Antipsychotic Medication Use Among Publicly Insured Pregnant Women in the United States. Psychiatric Services, 2017, 68, 1112-1119.	1,1	41
33	Risk of venous thromboembolism associated with tofacitinib in patients with rheumatoid arthritis: a population-based cohort study. Rheumatology, 2021, 61, 121-130.	0.9	41
34	Factors associated with initial or subsequent choice of biologic disease-modifying antirheumatic drugs for treatment of rheumatoid arthritis. Arthritis Research and Therapy, 2017, 19, 159.	1.6	37
35	Development and Preliminary Validation of a Medicare Claims–Based Model to Predict Left Ventricular Ejection Fraction Class in Patients With Heart Failure. Circulation: Cardiovascular Quality and Outcomes, 2018, 11, e004700.	0.9	36
36	An evaluation of longitudinal changes in serum uric acid levels and associated risk of cardio-metabolic events and renal function decline in gout. PLoS ONE, 2018, 13, e0193622.	1.1	33

#	Article	IF	CITATIONS
37	Medication Errors During Patient Transitions into Nursing Homes: Characteristics and Association With Patient Harm. American Journal of Geriatric Pharmacotherapy, 2011, 9, 413-422.	3.0	32
38	Temporal Trends in Use of Biologic DMARDs for Rheumatoid Arthritis in the United States: A Cohort Study of Publicly and Privately Insured Patients. Journal of Managed Care & Decialty Pharmacy, 2017, 23, 809-814.	0.5	30
39	Patterns of opioid initiation at first visits for pain in United States primary care settings. Pharmacoepidemiology and Drug Safety, 2018, 27, 495-503.	0.9	30
40	Predictors of Treatment Initiation with Tumor Necrosis Factor- $\hat{l}_{\pm}$ Inhibitors in Patients with Rheumatoid Arthritis. Journal of Managed Care Pharmacy, 2014, 20, 1110-1120.	2.2	29
41	Tumor Necrosis Factor-α Inhibitor Treatment and the Risk of Incident Cardiovascular Events in Patients with Early Rheumatoid Arthritis: A Nested Case-control Study. Journal of Rheumatology, 2014, 41, 2129-2136.	1.0	28
42	Diseaseâ€Modifying Antirheumatic Drug Use and the Risk of Incident Hyperlipidemia in Patients With Early Rheumatoid Arthritis: A Retrospective Cohort Study. Arthritis Care and Research, 2015, 67, 457-466.	1.5	28
43	Brief Report: Patterns and Secular Trends in Use of Immunomodulatory Agents During Pregnancy in Women With Rheumatic Conditions. Arthritis and Rheumatology, 2016, 68, 1183-1189.	2.9	27
44	Differences in rates of switchbacks after switching from branded to authorized generic and branded to generic drug products: cohort study. BMJ: British Medical Journal, 2018, 361, k1180.	2.4	27
45	Cardiovascular Outcomes of Calcium-Free vs Calcium-Based Phosphate Binders in Patients 65 Years or Older With End-stage Renal Disease Requiring Hemodialysis. JAMA Internal Medicine, 2019, 179, 741.	2.6	27
46	Gabapentin in pregnancy and the risk of adverse neonatal and maternal outcomes: A population-based cohort study nested in the US Medicaid Analytic eXtract dataset. PLoS Medicine, 2020, 17, e1003322.	3.9	27
47	Association of Geography and Access to Health Care Providers With Longâ€Term Prescription Opioid Use inÂMedicare Patients With Severe Osteoarthritis: AÂCohortÂStudy. Arthritis and Rheumatology, 2019, 71, 712-721.	2.9	26
48	Exploratory Evaluation of Medication Classes Most Commonly Involved in Nursing Home Errors. Journal of the American Medical Directors Association, 2013, 14, 403-408.	1.2	25
49	Use of prescription opioids among patients with rheumatic diseases compared to patients with hypertension in the USA: a retrospective cohort study. BMJ Open, 2019, 9, e027495.	0.8	25
50	Broadening the reach of the FDA Sentinel system: A roadmap for integrating electronic health record data in a causal analysis framework. Npj Digital Medicine, 2021, 4, 170.	5.7	25
51	Comparative Risk of Harm Associated With the Use of Targeted Immunomodulators: A Systematic Review. Arthritis Care and Research, 2016, 68, 1078-1088.	1.5	24
52	Performance of Disease Risk Score Matching in Nested Case-Control Studies: A Simulation Study. American Journal of Epidemiology, 2016, 183, 949-957.	1.6	24
53	Using Realâ€World Data to Extrapolate Evidence From Randomized Controlled Trials. Clinical Pharmacology and Therapeutics, 2019, 105, 1156-1163.	2.3	22
54	Risk of exacerbation of pulmonary comorbidities in patients with rheumatoid arthritis after initiation of abatacept versus TNF inhibitors: A cohort study. Seminars in Arthritis and Rheumatism, 2020, 50, 401-408.	1.6	19

#	Article	IF	CITATIONS
55	Utilization and Treatment Costs of Tumor Necrosis Factor Inhibitors After the Introduction of Biosimilar Infliximab in the United States. Arthritis and Rheumatology, 2020, 72, 1036-1038.	2.9	19
56	Tumor Necrosis Factor- $\hat{l}_{\pm}$ Inhibitor Use and the Risk of Incident Hypertension in Patients with Rheumatoid Arthritis. Epidemiology, 2016, 27, 414-422.	1,2	18
57	Association between inflammation and systolic blood pressure in RA compared to patients without RA. Arthritis Research and Therapy, 2018, 20, 107.	1.6	18
58	Contemporary Time Trends in Use of Antiplatelet Agents Among Patients with Acute Coronary Syndrome and Comorbid Diabetes Mellitus or Chronic Kidney Disease. Pharmacotherapy, 2017, 37, 1322-1327.	1.2	16
59	Using prescription claims to detect aberrant behaviors with opioids: comparison and validation of 5 algorithms. Pharmacoepidemiology and Drug Safety, 2019, 28, 62-69.	0.9	16
60	Effectiveness of angiotensin-neprilysin inhibitor treatment versus renin-angiotensin system blockade in older adults with heart failure in clinical care. Heart, 2021, 107, 1407-1416.	1.2	16
61	Comparative Risk of Alzheimer Disease and Related Dementia Among Medicare Beneficiaries With Rheumatoid Arthritis Treated With Targeted Disease-Modifying Antirheumatic Agents. JAMA Network Open, 2022, 5, e226567.	2.8	16
62	Mixed Treatment Comparison of the Treatment Discontinuations of Biologic Disease-Modifying Antirheumatic Drugs in Adults with Rheumatoid Arthritis. Annals of Pharmacotherapy, 2012, 46, 1491-1505.	0.9	15
63	Comparative effectiveness of individual angiotensin receptor blockers on risk of mortality in patients with chronic heart failure. Pharmacoepidemiology and Drug Safety, 2012, 21, 233-240.	0.9	15
64	Calcium Channel Blocker Exposure in Late Pregnancy and the Risk of Neonatal Seizures. Obstetrics and Gynecology, 2015, 126, 271-278.	1.2	15
65	The "Dry-Run―Analysis: A Method for Evaluating Risk Scores for Confounding Control. American Journal of Epidemiology, 2017, 185, 842-852.	1.6	15
66	Association of Medicare's Bundled Payment Reform With Changes in Use of Vitamin D Among Patients Receiving Maintenance Hemodialysis: An Interrupted Time-Series Analysis. American Journal of Kidney Diseases, 2018, 72, 178-187.	2.1	15
67	<p>Risk Factors for Heart Failure with Preserved or Reduced Ejection Fraction Among Medicare Beneficiaries: Application of Competing Risks Analysis and Gradient Boosted Model</p> . Clinical Epidemiology, 2020, Volume 12, 607-616.	1.5	15
68	Correlation Between Changes in Brand-Name Drug Prices and Patient Out-of-Pocket Costs. JAMA Network Open, 2021, 4, e218816.	2.8	15
69	Comparative risk of incident venous thromboembolism in patients with inflammatory bowel disease initiating tumour necrosis factor- $\hat{l}_{\pm}$ inhibitors or nonbiologic agents: a cohort study. Cmaj, 2017, 189, E1438-E1447.	0.9	14
70	Epidemiologic Characterization of Heart Failure with Reduced or Preserved Ejection Fraction Populations Identified Using Medicare Claims. American Journal of Medicine, 2021, 134, e241-e251.	0.6	14
71	An external validation study reporting poor correlation between the claims-based index for rheumatoid arthritis severity and the disease activity score. Arthritis Research and Therapy, 2015, 17, 83.	1.6	13
72	Patterns of Systemic Treatment for Psoriatic Arthritis in the US: 2004-2015. Arthritis Care and Research, 2018, 70, 791-796.	1.5	13

#	Article	IF	Citations
73	Medicaid Expansion and Utilization of Antihyperglycemic Therapies. Diabetes Care, 2020, 43, 2684-2690.	4.3	13
74	External validation of a claims-based model to predict left ventricular ejection fraction class in patients with heart failure. PLoS ONE, 2021, 16, e0252903.	1.1	13
75	Suppression of Substance Abuse Claims in Medicaid Data and Rates of Diagnoses for Non–Substance Abuse Conditions. JAMA - Journal of the American Medical Association, 2016, 315, 1164.	3.8	12
76	Utilization Patterns of Oral Disease-Modifying Drugs in Commercially Insured Patients with Multiple Sclerosis. Journal of Managed Care & Specialty Pharmacy, 2019, 25, 113-121.	0.5	12
77	Bias Implications of Outcome Misclassification in Observational Studies Evaluating Association Between Treatments and Allâ€Cause or Cardiovascular Mortality Using Administrative Claims. Journal of the American Heart Association, 2020, 9, e016906.	1.6	12
78	Clinical outcomes and healthcare utilization in patients with sickle cell disease: a nationwide cohort study of Medicaid beneficiaries. Annals of Hematology, 2020, 99, 2497-2505.	0.8	12
79	Decreased risk of treatment failure with vedolizumab and thiopurines combined compared with vedolizumab monotherapy in Crohn's disease. Gut, 2022, 71, 1781-1789.	6.1	11
80	Analgesic Medication Errors in North Carolina Nursing Homes. Journal of Pain and Palliative Care Pharmacotherapy, 2013, 27, 125-131.	0.5	10
81	Practice Pattern of Hepatitis B Testing in Rheumatoid Arthritis Patients: A Crossâ€National Comparison Between the US and Taiwan. Arthritis Care and Research, 2018, 70, 30-38.	1.5	10
82	Evaluation of Socioeconomic Status Indicators for Confounding Adjustment in Observational Studies of Medication Use. Clinical Pharmacology and Therapeutics, 2019, 105, 1513-1521.	2.3	10
83	Targeting abnormal metabolism in Alzheimer's disease: The Drug Repurposing for Effective Alzheimer's Medicines (DREAM) study. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2020, 6, e12095.	1.8	10
84	Comparative Risk of Diabetes Mellitus in Patients With Rheumatoid Arthritis Treated With Biologic or Targeted Synthetic Diseaseâ€Modifying Drugs: A Cohort Study. ACR Open Rheumatology, 2020, 2, 222-231.	0.9	10
85	Prescription opioid use after vaginal delivery and subsequent persistent opioid use and misuse. American Journal of Obstetrics & Synecology MFM, 2021, 3, 100304.	1.3	10
86	Anticoagulant medication errors in nursing homes: Characteristics, causes, outcomes, and association with patient harm. Journal of Healthcare Risk Management: the Journal of the American Society for Healthcare Risk Management, 2013, 33, 33-43.	0.3	9
87	Comparative effectiveness and safety of antiplatelet drugs in patients with diabetes mellitus and acute coronary syndrome. Pharmacoepidemiology and Drug Safety, 2018, 27, 1361-1370.	0.9	9
88	Risk of Serious Infection Among Initiators of Tumor Necrosis Factor Inhibitors Plus Methotrexate Versus Triple Therapy for Rheumatoid Arthritis: A Cohort Study. Arthritis Care and Research, 2020, 72, 1383-1391.	1.5	9
89	Use of Time-Dependent Propensity Scores to Adjust Hazard Ratio Estimates in Cohort Studies with Differential Depletion of Susceptibles. Epidemiology, 2020, 31, 82-89.	1.2	9
90	Changes in Utilization of Generic Angiotensin Receptor Blockers Following Product Recalls in the United States. JAMA - Journal of the American Medical Association, 2020, 323, 87.	3.8	9

#	Article	IF	Citations
91	Updated Assessment of Cardiovascular Risk in Older Patients With Gout Initiating Febuxostat Versus Allopurinol. Journal of the American Heart Association, 2021, 10, e020045.	1.6	9
92	Risk of venous thromboembolism associated with methotrexate versus hydroxychloroquine for rheumatoid arthritis: A propensity score-matched cohort study. Seminars in Arthritis and Rheumatism, 2021, 51, 1242-1250.	1.6	9
93	Extension of Disease Risk Score–Based Confounding Adjustments for Multiple Outcomes of Interest: An Empirical Evaluation. American Journal of Epidemiology, 2018, 187, 2439-2448.	1.6	8
94	Methodologic considerations for noninterventional studies of switching from reference biologic to biosimilars. Pharmacoepidemiology and Drug Safety, 2020, 29, 757-769.	0.9	8
95	Chronic prescription opioid use in pregnancy in the United States. Pharmacoepidemiology and Drug Safety, 2021, 30, 504-513.	0.9	7
96	Comparative Risk of Nonvertebral Fractures Among Patients With Rheumatoid Arthritis Treated With Biologic or Targeted Synthetic Diseaseâ€Modifying Antirheumatic Drugs. ACR Open Rheumatology, 2021, 3, 531-539.	0.9	7
97	Predicting overdose among individuals prescribed opioids using routinely collected healthcare utilization data. PLoS ONE, 2020, 15, e0241083.	1.1	7
98	The Potential Return on Public Investment in Detecting Adverse Drug Effects. Medical Care, 2017, 55, 545-551.	1.1	6
99	The Patterns of Use of Medications for Inflammatory Bowel Disease During Pregnancy in the US and Sweden Are Changing. Inflammatory Bowel Diseases, 2021, 27, 1427-1434.	0.9	6
100	Medication Burden and Prescribing Patterns in Patients on Hemodialysis in the USA, 2013–2017. American Journal of Nephrology, 2021, 52, 919-928.	1.4	6
101	Effect of Lawyer-Submitted Reports on Signals of Disproportional Reporting in the Food and Drug Administration's Adverse Event Reporting System. Drug Safety, 2019, 42, 85-93.	1.4	5
102	Risk of Uveitis in Patients With Inflammatory Bowel Disease on Immunosuppressive Drug Therapy. Crohn's & Colitis 360, 2020, 2, .	0.5	5
103	Clinical outcomes following bone marrow transplantation in patients with sickle cell disease: A cohort study of US Medicaid enrollees. European Journal of Haematology, 2021, 106, 273-280.	1.1	5
104	Calibrating Realâ€World Evidence Studies Against Randomized Trials: Treatment Effectiveness of Infliximab in Crohn's Disease. Clinical Pharmacology and Therapeutics, 2022, 111, 179-186.	2.3	5
105	Secular Trends in the Pharmacologic Treatment of Osteoporosis and Malignancy-Related Bone Disease from 2009 to 2020. Journal of General Internal Medicine, 2022, 37, 1917-1924.	1.3	5
106	Emulation of a randomized controlled trial in ulcerative colitis with <scp>US</scp> and French claims data: Infliximab with thiopurines compared to infliximab monotherapy. Pharmacoepidemiology and Drug Safety, 2022, 31, 167-175.	0.9	5
107	Rates of Spironolactone Initiation and Subsequent Hyperkalemia Hospitalizations in Patients with Heart Failure with Preserved Ejection Fraction Following the TOPCAT trial: A Cohort Study of Medicare Beneficiaries. Journal of Cardiac Failure, 2022, 28, 1035-1039.	0.7	5
108	Applying Machine Learning in Distributed Data Networks for Pharmacoepidemiologic and Pharmacovigilance Studies: Opportunities, Challenges, and Considerations. Drug Safety, 2022, 45, 493-510.	1.4	5

#	Article	IF	Citations
109	Use of large healthcare databases for rheumatology clinical research. Current Opinion in Rheumatology, 2017, 29, 138-143.	2.0	4
110	Anticonvulsants and the risk of perinatal bleeding complications. Neurology, 2018, 91, e533-e542.	1.5	4
111	Unraveling the Role of Nonsteroidal Antiinflammatory Drugs in the Link Between Osteoarthritis and Cardiovascular Disease via Causal Mediation Analysis: A Guide to Interpretation. Arthritis and Rheumatology, 2019, 71, 1776-1779.	2.9	4
112	Evaluating the use of bootstrapping in cohort studies conducted with 1:1 propensity score matchingâ€"A plasmode simulation study. Pharmacoepidemiology and Drug Safety, 2019, 28, 879-886.	0.9	4
113	Drug use trends for arthritis and other rheumatic conditions and effect of patient's age on treatment choice. North Carolina Medical Journal, 2011, 72, 432-8.	0.1	3
114	Comment on: Risk of major adverse cardiovascular events in patients initiating biologics/apremilast for psoriatic arthritis: a nationwide cohort study. Rheumatology, 2022, 61, e236-e237.	0.9	3
115	Variation in adherence to medications across the healthcare system in two comparative effectiveness research cohorts. Journal of Comparative Effectiveness Research, 2017, 6, 613-625.	0.6	2
116	Comparative Outcomes of Treatment Initiation With Brand vs. Generic Warfarin in Older Patients. Clinical Pharmacology and Therapeutics, 2020, 107, 1334-1342.	2.3	2
117	Using Healthcare Databases to Replicate Trial Findings for Supplemental Indications: Adalimumab in Patients with Ulcerative Colitis. Clinical Pharmacology and Therapeutics, 2020, 108, 874-884.	2.3	2
118	Use of Anticoagulants and Dosing Appropriateness of Apixaban for New-Onset Atrial Fibrillation Among Hemodialysis Patients. American Journal of Kidney Diseases, 2022, 79, 909-912.	2.1	2
119	Medication Burden in Older Patients With Heart Failure: A Cohort Study of Medicare Beneficiaries. Journal of Cardiac Failure, 2020, 26, 742-744.	0.7	2
120	Statin Lipophilicity and the Risk of Incident Heart Failure. Cardiology, 2020, 145, 375-383.	0.6	1
121	Development of a Medicare Claims–Based Model to Predict Persistent Highâ€Dose Opioid Use After Total Knee Replacement. Arthritis Care and Research, 2022, 74, 1342-1348.	1.5	1
122	Temporal Trends in Prescribing of Bone-Directed Therapies in the United States, 2009–2020. Journal of the Endocrine Society, 2021, 5, A250-A250.	0.1	1
123	Influenza Vaccine Uptake in the Year After Concurrent vs Separate Influenza and Zoster Immunization. JAMA Network Open, 2021, 4, e2135362.	2.8	1
124	Reply. Obstetrics and Gynecology, 2014, 124, 638.	1.2	0
125	Alendronate and Hip Fracture in Patients Using Glucocorticoids. JAMA - Journal of the American Medical Association, 2017, 318, 1711.	3.8	0
126	Clinical Outcomes Following Bone Marrow Transplant in Patients with Sickle Cell Disease: A Cohort Study of US Medicaid Enrollees. Blood, 2019, 134, 2166-2166.	0.6	0

#	Article	IF	CITATIONS
127	Title is missing!. , 2020, 17, e1003322.		0
128	Title is missing!. , 2020, 17, e1003322.		0
129	Title is missing!. , 2020, 17, e1003322.		0
130	Title is missing!. , 2020, 17, e1003322.		0
131	Title is missing!. , 2020, 17, e1003322.		0
132	Title is missing!. , 2020, 17, e1003322.		0
133	Title is missing!. , 2020, 17, e1003322.		0
134	Title is missing!. , 2020, 17, e1003322.		0
135	Title is missing!. , 2020, 17, e1003322.		0